

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A pharmaceutical composition comprising (a) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from citalopram, escitalopram and salts thereof.

2-36. (canceled).

37. (previously presented): A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from citalopram and salts thereof.

38. (previously presented): The pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and a salt thereof.

39. (canceled).

40. (previously presented): The composition of any one of claims 1, 37 and 38 wherein aripiprazole is anhydrous aripiprazole crystals B.

41. (previously presented): The composition of any one of claims 1, 37 and 38 further comprising at least one pharmaceutically acceptable carrier.

42. (canceled).

43. (previously presented): The composition of any one of claims 1, 37 and 38 being useful for the treatment of depression or major depressive disorder.

44. (previously presented): The composition of any one of claims 1, 37 and 38 being useful for the treatment of major depressive disorder dementia with depressive symptoms.

45. (previously presented): The composition of any one of claims 1, 37 and 38 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

46.-53. (canceled).

54. (previously presented): A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition which comprise(s) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of citalopram, escitalopram and salts thereof.

55. (previously presented): A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory

depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of citalopram, and salts thereof.

56. (previously presented): The method of a treating mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof.

57. (canceled).

58. (previously presented): The method of any one of claims 54 to 56, wherein aripiprazole is anhydrous aripiprazole crystals B.

59. (previously presented): The method of any one claims 54 to 56, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

60. (previously presented): The method of any one claims 54 to 56, being useful for the treatment of depression of major depressive disorder.

61. (previously presented): The method of any one of claims 54 to 56, being useful for the treatment of major depressive disorder or dementia with depressive symptoms.

62. (previously presented): The method of any one of claims 54 to 56, being useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

63.-69. (canceled).

70. (new): The composition of claim 41, wherein the at least one pharmaceutically acceptable carrier is selected from the group consisting of fillers, extenders, binders, moisturizers, disintegrants, surfactants and lubricants.

71. (new): The composition of claim 1, wherein the amount of (a) aripiprazole in combination with (b) at least one serotonin reuptake inhibitor selected from citalopram, escitalopram and salts thereof is 1 to 70 parts by weight of the total composition.